Acrivon ipo pricing
WebAcrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo Finance U.S. markets closed Acrivon Therapeutics, Inc. (ACRV) NasdaqGM - NasdaqGM Real … WebNov 15, 2024 · The firm will use the funds from the IPO to advance Acrivon's lead candidate, the CHK1 and CHK2 inhibitor ACR-368. ... Acrivon Therapeutics Prices $99.4M Initial Public Offering Nov 15, 2024 staff reporter Save for later Acrivon's shares will begin trading on the Nasdaq Global Market on Nov. 15 under the ticker symbol "ACRV." ...
Acrivon ipo pricing
Did you know?
WebNov 15, 2024 · After delaying its offering by a few days, the company sold 7,550,000 shares at $12.50 apiece. It also agreed to sell another 400,000 shares at the IPO price to its top … WebNov 9, 2024 · Acrivon announced last Thursday that it would be offering 5.9 million shares at a range between $16.00 to $18.00. The IPO is due to price on Wednesday night, November 9, before floating on...
Web2 days ago · Stock Price $ 8.79 Market Cap Chart No chart data available Since the IPO on November 15, 2024, Acrivon Therapeutics, Inc.'s market cap has decreased from … WebNov 8, 2024 · Precision oncology drug developer Acrivon Therapeutics (ACRV) has updated terms for a proposed $100M initial public offering, which would make it one of …
WebApr 10, 2024 · Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the … Web9 rows · Nov 14, 2024 · Acrivon’s shares are expected to begin trading on the Nasdaq Global Market on November 15, 2024 ...
WebApr 12, 2024 · According to analysts' consensus price target of $21.00, Acrivon Therapeutics has a forecasted upside of 138.9% from its current price of $8.79. Amount of Analyst Coverage Acrivon Therapeutics has received no research coverage in the past 90 days. See Top Rated MarketRank™ Stocks Here About Acrivon Therapeutics …
WebNov 3, 2024 · Acrivon Therapeutics, a Phase 2 biotech developing precision oncology therapies, announced terms for its IPO on Thursday. The Watertown, MA-based company plans to raise $100 million by offering 5.9 million shares at a price range of $16 to $18. alcyone m c vellozo c e prof ef mWebNov 15, 2024 · Acrivon Becomes Biotech's 20th IPO of 2024 with $99M Offering. Just the 20th company to go public amid this year's bear market, Acrivon Therapeutics … alcyone medicalWebNov 7, 2024 · A Watertown startup testing a drug licensed from Eli Lilly & Co. in midstage trials has filed for a $100 million IPO. Acrivon Therapeutics Inc. is scheduled to pull off the deal this week ... alcyone mediaWebApr 13, 2024 · Acrivon Therapeutics, Inc. ( NASDAQ:ACRV – Get Rating )’s share price traded down 5.6% on Wednesday . The stock traded as low as $8.86 and last traded at … alcyone miningWebNov 15, 2024 · Acrivon Therapeutics, a Phase 2 biotech developing proteomics-based precision oncology therapies, raised $94 million by offering 7.6 million shares at $12.50, well below the range of $16 to $18. The company offered 1.7 million more shares than anticipated, and prior to pricing, it had disclosed insider indications on 88% of shares in … alcyone metzWebAcrivon is developing targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon’s proprietary patient selection method is designed to profoundly … alcyone mitoWebAbout. We are a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature® companion diagnostics to identify the patients who will benefit from our medicines. The name Acrivon ... alcyone plantation